Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.

Int J Mol Sci · 2020 · PMC7504231 · PMID 32878115

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Regardless, the trial revealed a clear trend toward an OS improvement with nivolumab versus sorafenib, and thus exploration of nivolumab in HCC will continue.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.